By Matteo Castia 



  AstraZeneca PLC said Tuesday that the phase 3 of the trial for its Farxiga drug against kidney diseases showed a significant reduction in risk of death for patients and a slower illness progression. 


  The pharma giant said the risk of renal function worsening or cardiovascular and renal death was 39% lower compared to placebo in patients with chronic kidney disease. 


  Chronic kidney disease is a progressive condition defined by decreased kidney function. Farxiga is an oral, once-daily sodium-glucose co-transporter-2 inhibitor indicated in adults as both monotherapy and as part of combination therapy. 


  Write to Matteo Castia at matteo.castia@dowjones.com